California biopharmaceutical company ABVC Biopharma, a company focused on drug and medical device development, is expected to conduct a public offering of units comprised of one share of common stock and one series A warrant each. The company, which is currently listed on the Over-the-Counter Markets under the ticker symbol "ABVC," has applied for listing on the Nasdaq. The offering of units is contingent upon Nasdaq approving this listing. If approved, ABVC's stock will trade under the ticker symbol "ABVC."
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.41 - $2.45 |
| 50-day moving average | $0.60 |
| 200-day moving average | $0.88 |
| Wall St. target price | $2.02 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.81 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.522 from 2024-11-25
| 1 week (2024-11-19) | -0.61% |
|---|---|
| 1 month (2024-10-25) | -24.58% |
| 3 months (2024-08-26) | -26.48% |
| 6 months (2024-05-24) | -44.17% |
| 1 year (2023-11-24) | -74.16% |
|---|---|
| 2 years (2022-11-23) | N/A |
| 3 years (2021-11-26) | 32 |
| 5 years (2019-11-26) | 67 |
| Revenue TTM | $136,396 |
|---|---|
| Gross profit TTM | $350,711 |
| Return on assets TTM | -44.55% |
| Return on equity TTM | -320.36% |
| Profit margin | 0% |
| Book value | $1.06 |
| Market Capitalization | $6.7 million |
TTM: trailing 12 months
We're not expecting ABVC Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
ABVC Biopharma's shares were split on a 1:10 basis on 24 July 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ABVC Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ABVC Biopharma shares which in turn could have impacted ABVC Biopharma's share price.
Over the last 12 months, ABVC Biopharma's shares have ranged in value from as little as $0.4053 up to $2.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ABVC Biopharma's is 0.816. This would suggest that ABVC Biopharma's shares are less volatile than average (for this exchange).
To put ABVC Biopharma's beta into context you can compare it against those of similar companies.
ABVC BioPharma, Inc. , a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.